MedPath

Study of optimal treatment duration with antihistamine in idiopathic urticaria patients

Not Applicable
Conditions
Idiopathic urticaria
Registration Number
JPRN-UMIN000001163
Lead Sponsor
West Japan Urticaria Therapy Study Group
Brief Summary

1. Less patients (70%) in the treated group suffered from recurrences than in the control group (90%). 2. Urticaria scores of patients in the last week of the study, and a number of patients who were either suffering from symptoms or taking medications in the treated group were lower than those in the control group. 3. No relation was observed between the recurrence rate and time to the treatment, time to be symptom-free from the onset of urticaria, and severity of urticaria before the treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
93
Inclusion Criteria

Not provided

Exclusion Criteria

1. Pregnant or lactating women or women of child bearing potential not using contraception 2. Patients with a history of hypersensitivity to fexofenadine hydrochloride 3. Patients who use medications that interfere with the efficacy evaluation (e.g., other antihistamines, drugs with anti-allergy action, systemic steroids etc.) 4. Others whom the physician judges are not suitable as subjects

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cumulative recurrence rate at 3 months after relief of urticaria symptoms (signs)
Secondary Outcome Measures
NameTimeMethod
1. Cumulative recurrence rate at 4 and 8 weeks after the relief of urticaria symptoms(signs) 2. Safety
© Copyright 2025. All Rights Reserved by MedPath